(Q37360620)

19 August 2017

1 reference

title

Bendamustine: a new look at an old drug (English)

1 reference

19 August 2017

1 reference

Matt Kalaycio

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

19 August 2017

1 reference

19 August 2017

volume

115

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

473-479

1 reference

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

In vitro studies with bendamustine: enhanced activity in combination with rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24057

7 January 2021

Identifiers

DOI

10.1002/CNCR.24057

1 reference

19 August 2017

1 reference